Evidence map›Paper›PMID 34643885›Full record

ArticleClinical journal of gastroenterology2021

Rescue liver re-transplantation after graft loss due to severe rejection in the setting of pre-transplant nivolumab therapy.

Yalda Dehghan, Gabriel T Schnickel, Mojgan Hosseini, Adam M Burgoyne, Veeral H Ajmera, Gerald P Morris, Michel H Mendler, Justin R Parekh, Farid Abushamat, Irine Vodkin and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical journal of gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. New Scenarios in Liver Transplantation for Hepatocellular Carcinoma.Liver international : official journal of the International Association for the Study of the Liver · 2025
    Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Yalda DehghanDivision of Gastroenterology and Hepatology, Department of Medicine, University of California San Diego, La Jolla, CA, USA.
Gabriel T SchnickelDepartment of Surgery, Division of Transplant and Hepatobiliary Surgery, University of California San Diego School of Medicine, La Jolla, CA, USA.
Mojgan HosseiniDepartment of Pathology, University of California San Diego, La Jolla, CA, USA.
Adam M BurgoyneDivision of Hematology-Oncology, Department of Medicine, Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.
Veeral H AjmeraDivision of Gastroenterology and Hepatology, Department of Medicine, University of California San Diego, La Jolla, CA, USA.
Gerald P MorrisDepartment of Pathology, University of California San Diego, La Jolla, CA, USA.
Michel H MendlerDivision of Gastroenterology and Hepatology, Department of Medicine, University of California San Diego, La Jolla, CA, USA.
Justin R ParekhDepartment of Surgery, Division of Transplant and Hepatobiliary Surgery, University of California San Diego School of Medicine, La Jolla, CA, USA.
Farid AbushamatDivision of Gastroenterology and Hepatology, Department of Medicine, University of California San Diego, La Jolla, CA, USA.
Irine VodkinDivision of Gastroenterology and Hepatology, Department of Medicine, University of California San Diego, La Jolla, CA, USA.
Yuko KonoDivision of Gastroenterology and Hepatology, Department of Medicine, University of California San Diego, La Jolla, CA, USA. ykono@health.ucsd.edu.ORCID http://orcid.org/0000-0002-9357-4104
University of California San Diego · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint inhibitors (ICI) have been used to treat hepatocellular carcinoma (HCC) since 2017. The safety of ICIs in the setting of solid organ transplantation remains controversial. When used in the post-transplant setting, ICIs have been associated with high allograft rejection rates, but there are few published reports on the use of ICIs prior to transplant. We present the first reported case of rescue liver re-transplantation after loss of the first allograft due to severe acute rejection with extensive hepatic necrosis in the setting of pre-transplant ICI therapy with the PD-1 inhibitor nivolumab. It is likely that the durable immune response triggered by nivolumab contributes to graft rejection, therefore extreme caution should be taken when using ICIs before transplant until further investigation has been conducted on their safety in the pre-transplant setting.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsGraft RejectionHumansNivolumabNivolumabAcute rejectionHepatologyImmune regulationLiver transplantationMalignancy

Identifiers

PMID34643885
PMCPMC8557174
OpenAlexW3204998025

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.